Accuray (ARAY) Net Income towards Common Stockholders (2010 - 2026)
Accuray's (ARAY) quarterly Net Income towards Common Stockholders came in at -$12.2 million in Q1 2026, down 348.01% year-on-year from $4.9 million in Q1 2025, and up 14.2% quarter-over-quarter from -$14.2 million in Q4 2025.
Accuray (ARAY) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Accuray's Net Income towards Common Stockholders history runs 17 years deep, the most recent figure standing at -$12.2 million for Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders fell 348.01% year-over-year to -$12.2 million in Q1 2026; TTM through Mar 2026 was -$54.9 million, a 33582.93% decrease from a year earlier, with the FY2025 full-year figure at -$1.6 million, up 89.77% from the prior year.
- Net Income towards Common Stockholders grew to -$12.2 million in Q1 2026 per ARAY's latest filing, from -$14.2 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $4.3 million in Q2 2024 and bottomed at -$21.7 million in Q3 2025.
- The 5-year median for Net Income towards Common Stockholders is -$5.4 million (2022), against an average of -$6.9 million.
- Across the five-year window, Net Income towards Common Stockholders plunged 1191.44% in 2022 and surged 203.72% in 2024, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at -$1.9 million in 2022, then sank by 413.39% to -$9.6 million in 2023, then surged by 126.37% to $2.5 million in 2024, then tumbled by 658.57% to -$14.2 million in 2025, then increased by 14.2% to -$12.2 million in 2026.
- Per Business Quant, the three latest ARAY Net Income towards Common Stockholders figures stand at -$12.2 million (Q1 2026), -$14.2 million (Q4 2025), and -$21.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 199.50 Mn |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 411.00 Mn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 176.78 Mn |
| 10 | Accuray | 27,968.40 | -38.51 Mn | 25.29 Mn | -12.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.16 Mn |
| Dec 31, 2025 | -14.17 Mn |
| Sep 30, 2025 | -21.68 Mn |
| Jun 30, 2025 | -6.90 Mn |
| Mar 31, 2025 | -2.71 Mn |
| Dec 31, 2024 | 2.54 Mn |
| Sep 30, 2024 | -3.95 Mn |
| Jun 30, 2024 | 4.30 Mn |
| Mar 31, 2024 | -18.93 Mn |
| Dec 31, 2023 | -9.62 Mn |
| Sep 30, 2023 | -2.97 Mn |
| Jun 30, 2023 | -4.14 Mn |
| Mar 31, 2023 | -6.72 Mn |
| Dec 31, 2022 | -1.87 Mn |
| Sep 30, 2022 | -5.45 Mn |
| Jun 30, 2022 | -11.35 Mn |
| Mar 31, 2022 | -1.96 Mn |
| Dec 31, 2021 | 179,000.00 |
| Sep 30, 2021 | -1.03 Mn |
| Jun 30, 2021 | 1.04 Mn |